Honors And Milestones
Current Locations:Home > ABOUT US > Honors And Milestones

Innovent has won the recognition of government and society since its founding. Some of the highlights are listed below:


    2017

  • 92017

    信达生物订立企业文化及企业核心价值观
  • 92017

    公司M1b项目获批“苏州市先进制造业重大项目”
  • 92017

    信达生物与中科院上海有机化学所达成4.57亿美元的战略合作,创下了“中国生物制药国际合作第一单”的历史记录
  • 82017

    中央电视台财经频道(CCTV-2)《经济半小时》栏目第二次专题报道了信达生物,点赞中国生物药发展速度
  • 72017

    获批“江苏省外资研发中心”
  • 62017

    Innovent received a grant from the “precision medicine research project” under the National Key R&D Plan program.
  • 62017

    A report in the People’s Daily highlights Innovent’s vision and mission to commercialize high quality biopharmaceutical products which are affordable to ordinary Chinese people.
  • 62017

    A report by CCTV detailed the experiences of Michael Yu, Innovent’s CEO, in founding Innovent
  • 52017

    Innovent IBI308 PD-1 product entered into phase III clinical trials
  • 52017

    People’s daily released a news article reporting on Michael and Innovent’s efforts in developing novel drugs with exclusive global intellectual property rights.
  • 42017

    The Wall Street Journal published a feature story titled "China Emerges as Powerhouse for Biotech Drugs”, that reported on Innovent Biologic’s rapid development and achievements in innovation.
  • 42017

    A report from CCTV-2’s program “economic hours” introduces Innovent’s R&D breakthroughs in novel anti-cancer drug discovery, which in return, have the potential to benefit vast numbers of Chinese patients.
  • 32017

    Strategic collaboration with Hanmi Pharmaceuticals.
  • 32017

    Outstanding Contribution Enterprise of Jiangsu Manufacturing Industry
  • 32017

    “The Most Innovative Pharmaceutical Company”
  • 12017

    Dr. Michael Yu, was selected as “CCTV Person of the Year in Innovation for Science and Technology in 2016”. The award was jointly organized by the CCTV Technology, the Ministry of Education, and the Chinese Academy of Engineering. Other co-winners of this award included “Long March 5”, “Tiangong 2”, and “Shenzhou 11”.
  • 12017

    China Top Ten Innovative Break-out Pharmaceutical Companies in 2016

    2016

  • 122016

    National High-tech enterprises
  • 122016

    Suzhou Enterprise Technology Center
  • 122016

    "Guangming Daily" published a long newsletter, reporting on Innovent's biological innovation
  • 112016

    Finished Series D Financing, raised $ 262M, creating new record in the biopharmaceutical industry
  • 112016

    People's Daily reported on Innovent's innovation achievements
  • 112016

    Outstanding Private Technology Enterprise, Jiangsu Province
  • 112016

    Engineering Technology Research Center of Jiangsu Province
  • 112016

    “Most Influential Company” Award, “1000 Talents Program”              Alignment, Suzhou
  • 102016

    The 2016 BayHelix Deal of the Year
  • 102016

    DP production line and quality system of Innovent passed a MultinationalCompany's GMP audit
  • 102016

    IBI305 enters clinical phase III study
  • 92016

    IBI303 enters clinical phase III study
  • 92016

    IBI308 enters clinical study
  • 82016

    IBI301 enters clinical phase III study
  • 72016

    The Top Ten Break Through Technology Entrepreneur Award of the Jiangsu Province
  • 72016

    One of the Top Ten Science and Technology Entrepreneurs of Suzhou City in 2016
  • 72016

    ”Key member of “Innovative and Entrepreneurship Talent in Suzhou (Major Innovative Team)”
  • 72016

    "333 high-level personnel training project" the first level of training objects, Jiangsu Province
  • 72016

    Xinhua Daily reported on Innovent’s strategic partnership with Eli Lilly, creating “Four Firsts” in China
  • 62016

    Innovent was selected to attend the national “12th Five-Year” Science and Technology Innovation Accomplishment exhibition
  • 62016

    Adimab and Innovent expand partnership for discovery of antibodies and bispecifics
  • 62016

    EpimAb and Innovent announce multi-target bispecific antibody collaboration
  • 42016

    Distinguished Entrepreneur, Jiangsu Province
  • 22016

    "The Top Private Enterprise Company Based on Science and Technology" in Suzhou for 2014-2015
  • 12016

    Mayor of Suzhou's Award on Innovation and Entrepreneurship

    2015

  • 122015

    "Ten Breakthroughs in the China Biopharmaceutical Industry" in 2015
  • 112015

    Ernst & Young Entrepreneur of The Year 2015
  • 112015

    Completed an audit by a Multinational Company's Global Quality team    on Innovent's quality systems and GMP production
  • 102015

    Innovent expanded the strategic alliance with Lilly to include three bispecific antibodies, with milestone payments totaling more than 1.3 billion US dollars
  • 72015

    People's Daily and Wall Street Journal covered Innovent's  achievements   in headline reports
  • 62015

    Innovent attended the 6th U.S.-China Innovation Dialogue
  • 32015

    Innovent Biologics established a strategic partnership with Eli Lilly
  • 12015

    Completed Series C Financing with Legend Capital as the lead investors  with Temasek and two other investment companies participation
  • 12015

    Top Ten Persons of Year of Innovation China in 2014

    2014

  • 92014

    The 1st IND application got approval for clinical trial
  • 62014

    New campus in operation
  • 32014

    Top Ten Newcomers Who touch the Heart of Suzhou Industrial Park in    2013
  • 22014

    Top Ten Science and Technology Figures of Suzhou in 2013

    2013

  • 122013

    BioBAY Responsibility Award in 2013
  • 72013

    Innovent initiated new therapeutic discovery Partnership with Adimab
  • 52013

    "Six Most Influential Overseas Returnee Talents in Life Sciences"in 2013
  • 22013

    Leading Figure of Innovation in Suzhou

    2012

  • 122012

    "Innovation Team" Award of Jiangsu Province
  • 122012

    "Innovative and Entrepreneurship Talent" of Jiangsu Province
  • 82012

    Suzhou R&D Center for Antibody
  • 62012

    Innovent-Sichuan University joint R&D Center
  • 62012

    Completed Series B Financing with Lilly Asia Ventures as the lead investor
  • 32012

    The contract of building the new campus was signed in the Great Hall of   the People

    2011

  • 102011

    Completed Series A Financing with Fidelity as the major investor
  • 82011

    Inception of Innovent Biologics
Copyright © 2011- Innovent Biologics, Inc.
Powered by RuiXi